Bank of America upgraded shares of Esperion Therapeutics (NASDAQ:ESPR) from an underperform rating to a neutral rating in a research report sent to investors on Monday morning, Briefing.com Automated Import reports.
A number of other research analysts have also issued reports on ESPR. Needham & Company LLC increased their target price on Esperion Therapeutics from $94.00 to $114.00 and gave the company a strong-buy rating in a research report on Monday, January 7th. Cowen restated a buy rating and issued a $94.00 price objective on shares of Esperion Therapeutics in a report on Tuesday, January 15th. BidaskClub upgraded Esperion Therapeutics from a sell rating to a hold rating in a report on Thursday, January 31st. Zacks Investment Research lowered Esperion Therapeutics from a hold rating to a sell rating in a report on Friday, February 8th. Finally, ValuEngine lowered Esperion Therapeutics from a buy rating to a hold rating in a report on Friday, February 8th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus target price of $75.42.
Shares of NASDAQ:ESPR opened at $48.24 on Monday. Esperion Therapeutics has a 1 year low of $35.80 and a 1 year high of $60.99. The company has a market cap of $1.16 billion, a PE ratio of -6.40 and a beta of 2.11.
Esperion Therapeutics (NASDAQ:ESPR) last announced its earnings results on Thursday, February 28th. The biopharmaceutical company reported ($2.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.30) by ($0.94). As a group, analysts expect that Esperion Therapeutics will post -2.93 earnings per share for the current fiscal year.
In other news, major shareholder Target N. V. Biotech acquired 50,000 shares of the firm’s stock in a transaction on Thursday, March 14th. The shares were bought at an average price of $49.89 per share, for a total transaction of $2,494,500.00. Following the acquisition, the insider now owns 3,522,964 shares of the company’s stock, valued at approximately $175,760,673.96. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Timothy M. Mayleben acquired 5,000 shares of the firm’s stock in a transaction on Thursday, March 14th. The stock was purchased at an average price of $48.73 per share, for a total transaction of $243,650.00. Following the acquisition, the chief executive officer now directly owns 51,163 shares in the company, valued at approximately $2,493,172.99. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 65,000 shares of company stock worth $3,155,550 and sold 48,329 shares worth $2,280,206. Company insiders own 7.70% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Rhumbline Advisers raised its holdings in shares of Esperion Therapeutics by 45.2% during the 4th quarter. Rhumbline Advisers now owns 31,583 shares of the biopharmaceutical company’s stock worth $1,453,000 after acquiring an additional 9,836 shares during the period. BB Biotech AG raised its holdings in shares of Esperion Therapeutics by 3.4% during the 4th quarter. BB Biotech AG now owns 3,392,964 shares of the biopharmaceutical company’s stock worth $156,076,000 after acquiring an additional 110,000 shares during the period. Teachers Advisors LLC raised its holdings in shares of Esperion Therapeutics by 35.1% during the 3rd quarter. Teachers Advisors LLC now owns 62,477 shares of the biopharmaceutical company’s stock worth $2,772,000 after acquiring an additional 16,237 shares during the period. Hsbc Holdings PLC purchased a new position in shares of Esperion Therapeutics during the 4th quarter worth $11,067,000. Finally, BlackRock Inc. raised its holdings in shares of Esperion Therapeutics by 4.1% during the 3rd quarter. BlackRock Inc. now owns 1,878,905 shares of the biopharmaceutical company’s stock worth $83,367,000 after acquiring an additional 73,673 shares during the period.
About Esperion Therapeutics
Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
Featured Article: Blue-Chip Stocks
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.